RxDoctor Payments Data

Zunaira Ghaffar, MD

Internal Medicine · Brooklyn, NYNPI 1861053761

Payments from drug & device makers

$3,202in general payments, 2019–2025

Across 73 payments — averaging $43.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$983
  • Johnson & Johnson$696
  • Novo Nordisk$476
  • Pfizer$207
  • Boehringer Ingelheim$154
  • Bayer$134
  • plus $551 from 12 others

What the payments were for

  • Food & beverage$3,202100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,202 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$36,952
Medicare patients
117
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol18$12,667
JanuviaSitagliptin Phosphate11$12,246
EntrestoSacubitril/Valsartan12$11,559
EliquisApixaban16$9,696
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,276
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,406
Nifedipine ErNifedipine27$594
Gabapentin33$391
Levetiracetam17$386
Atorvastatin Calcium64$335
Tamsulosin Hcl18$250
Metoprolol Succinate30$248
Finasteride19$229
Hydralazine Hcl14$168
Pantoprazole Sodium32$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$76$12,24611 claims
PfizerEliquis$207$9,69616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →